

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

OFFICIAL ORGAN OF THE INTERNATIONAL LEPROSY ASSOCIATION

EDITORIAL OFFICE

Gillis W. Long Hansen's Disease Center
at Louisiana State University
Baton Rouge, Louisiana 70894, U.S.A.

VOLUME 60, NUMBER 3

SEPTEMBER 1992

EDITORIALS

*Editorial opinions expressed are those of the writers.*One-Carbon Requirements of *Mycobacterium leprae*:
Need for the Folate Pathway**Why another article on DDS?**

The mode of action of dapsone (DDS) has been shown using classical methods; enzymes for folate biosynthesis have been demonstrated in *Mycobacterium leprae*. Yet, from time to time, doubts are still expressed on how DDS works. The argument goes: *M. leprae* is a parasite, and can fulfill its metabolic requirements by scavenging the products of its host's biosynthetic pathways. One-carbon (C-1) units, which are dependent on folate, are required essentially for biosynthetic reactions. Therefore, *M. leprae* should not have any metabolic requirement for C-1, for folate, and thus DDS cannot be acting (at least principally) on folate biosynthesis. However, I will argue in this editorial that *M. leprae* must indeed have C-1 metabolism, although its requirements for C-1 are likely to be far less than they would be for a free-living microbe.

I also wish to address a paradox: DDS kills *M. leprae* exceptionally slowly, or is bacteriostatic (Table 1), yet its effect on essentially nongrowing *M. leprae* in "viability tests" or drug screens is relatively rapid.

Alternative ideas for the mode of action of DDS¹

Apart from its effect on folate biosynthesis, DDS has immunomodulatory effects—mainly suppressive—and is an antioxidant. Thus, it has been suggested that DDS acts against *M. leprae* by perturbing the nutritional and immunological relationship between host and *M. leprae* or even by simply acting on the nutritional status of the host. There is a grain of truth in the concept which underlies these alternative ideas—that leprosy is a nutritional disease. The nutritional status of the host affects the working of the immune system. Then, availability of nutrients inside host cells determines the ability of intracellular parasites to grow and multiply. Sequestration of nutrients vital to intracellular parasites by the host, mediated by protective immune re-

¹ No references are attributed to the hypotheses; they were advanced imaginatively and in good faith to try to rationalize a puzzling disease. It is not the author's intent to set up sincere contributors just to knock them down. Nevertheless, there is little experimental evidence.

TABLE 1. Concentrations of DDS achieved in treatment and their biological effects.

Effects	Concentration	Footnotes
MIC (bacteriostatic)	0.014 μ M (3 ng/ml)	27, 28
Bacteriocidal	0.24 to 7 μ M	17, 18, 27, 28
I ₅₀ ^a	0.3 to 0.4 μ M	6, 8
Antioxidant	7 to 70 μ M	5
Concentration in serum:		
Mice fed with 0.01% DDS in diet	2.4 to 7 μ M	} 27, 28, 29
Humans on 50 to 100 mg DDS/day	(0.5 to 1.5 μ M)	

^a Concentration to give 50% inhibition of folate biosynthesis in cell extracts.

sponses, plays a part in controlling the parasites.²⁻⁴ However, I view the foregoing concept almost as a truism, certainly applicable to a wide range of parasitic and microbial diseases, and not helping to explain the unique antileprosy effect of DDS at low concentrations. Direct action as an antioxidant is extremely unlikely since the concentration at which antioxidant effects are evident with DDS is 1000 to 10,000 times its minimal inhibitory concentration (MIC).⁵

Action of DDS on folate biosynthesis

DDS is a competitive inhibitor of dihydropteroate synthetase in mycobacteria (The Figure). In contrast to the action of sulfones on *Escherichia coli*, no dihydropteroate analog is formed in mycobacteria. Thus, the enzyme-substrate, para-aminobenzoic acid (PABA), is able to antagonize the action of DDS.⁶ However, DDS has a much higher affinity for dihydropteroate synthetase from mycobacteria than from *E. coli*.⁶ This high

affinity for its target explains the relatively high sensitivity of *M. lufu* to DDS—*M. lufu* is a slow-growing but axenically cultivable microbe with a dihydropteroate synthetase for which DDS has a very similar affinity to the synthase of *M. leprae*. The extraordinary sensitivity of *M. leprae* to DDS is probably due to factors additional to the sensitivity of the target enzyme. It is possible that the concentration of PABA is low in *M. leprae*.⁶ Furthermore, it is likely that host cells concentrate DDS.⁷

DDS resistance is probably principally a result of overexpression of the gene for dihydropteroate synthetase since slightly increased enzyme is detected in resistant mycobacteria.⁶ There is no difference in the affinity of the enzyme for DDS between enzymes from sensitive or resistant strains of the same mycobacterium. The decreased permeability to DDS may be a possible resistance mechanism, but this is unlikely in the strains investigated so far since brodimoprim (The Figure) is synergistic with DDS in its antimycobacterial action.⁸ This latter observation depends upon dihydropteroate synthetase remaining sensitive to DDS (as established above) and DDS being able to enter the mycobacterium. The observations on DDS resistance were made in greatest detail with *M. lufu*, then shown to hold for *M. leprae*.

² Byrne, G. I., Lehmann, L. K. and Landry, G. J. Induction of tryptophan catabolism is the mechanism for gamma-interferon-mediated inhibition of intracellular *Chlamydia psittaci* replication in T24 cells. *Infect. Immun.* **53** (1986) 347–351.

³ Lepper, A. W. D. and Wilks, C. R. Intracellular iron storage and the pathogenesis of paratuberculosis. Comparative studies with other mycobacterial, parasitic or infectious conditions of veterinary importance. *J. Comp. Pathol.* **98** (1988) 31–53.

⁴ Pfefferkorn, E. R. Interferon gamma blocks the growth of *Toxoplasma gondii* in human fibroblasts by inducing the host cells to degrade tryptophan. *Proc. Nat. Acad. Sci. U.S.A.* **81** (1984) 908–912.


⁵ Bergel, M. Investigaciones farmacologicas y toxicologicas sobre las sulfonas. *Acta Leprol.* **57** (1974) 5–49.

⁶ Kulkarni, V. M. and Seydel, J. K. Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate synthesising systems prepared from *Mycobacterium lufu* and *Mycobacterium leprae*. *Chemotherapy* **29** (1983) 58–67.


⁷ Jagannathan, R. and Mahadevan, P. R. Minimum inhibitory concentration of drugs against *Mycobacterium leprae* as determined by an *in vitro* assay. *J. Biosci.* **10** (1986) 137–144.

⁸ Coates, E. A., Cordes, H.-P., Kulkarni, V. M., Richter, M., Schaper, K.-J., Weise, M. and Seydel, J. K. Multiple regression and principal component analysis of antibacterial activities of sulfones and sulfonamides in whole cell and cell-free systems of various DDS sensitive and resistant bacterial strains. *Quant. Struct. Act. Relat.* **4** (1985) 99–109.

In mycobacteria and in *E. coli*



Additional reaction in *E. coli* only: analogue formation



Code: Explanation Substrate-arrows show enzyme reactions
 Enzymes Inhibitors-arrows show targets

THE FIGURE. Pathway of folate biosynthesis.

One-carbon metabolism in *M. leprae*

For inhibitors of the folate pathway to work against *M. leprae*, the bacteria must have to synthesize products using the C-1 donors based on FH₄ (tetrahydrofolate) which are shown in Table 2.

The first clue that *M. leprae* carries out such biosynthetic reactions is that it contains the enzymes in the folate biosynthetic pathway that have been sought (The Fig-

ure). Both dihydrofolate reductase (DHFR)⁹ and dihydropteroate synthetase⁶ have been detected, the latter at 9% to 18% of the specific activity found in other mycobacteria

⁹ Seydel, J. K., Wempe, E. G., Rosenfield, M., Jagannathan, R. and Dhople, A. M. *In vitro* and *in vivo* experiments with the new inhibitor of *Mycobacterium leprae* brodimoprim alone and in combination with dapsone. *Arzheim. Forsch.* **40** (1990) 69-75.

TABLE 2. Products of C-1 transfer and their metabolism in *M. leprae*.

Product	Biosynthetic C-1 donor	Biosynthesis in <i>M. leprae</i>	Scavenging by <i>M. leprae</i>	Foot-notes
Serine	N ⁵ ,N ¹⁰ hydroxymethylene FH ₄	Not known	Yes	¹³
Methionine	N ⁵ methyl FH ₄	Yes	Not known but likely	¹¹
Purines	N ⁵ formimino FH ₄ N ⁵ ,N ¹⁰ methenyl FH ₄	No	Yes	¹³
Thymine cytosine bases	N ¹⁰ formyl FH ₄ N ⁵ ,N ¹⁰ methylene FH ₄	Yes	Yes, but thymine very slowly	¹²
f-Met-t-RNA	N ¹⁰ formyl FH ₄	Only sought and found in <i>M. smegmatis</i>	Not plausible	^{15,16}
Methylated DNA and methylated proteins	S-adenosyl methionine	Not known	Not plausible	—
Mono-, dimethyl or cyclopropyl fatty acids	S-adenosyl methionine	Must be	Not plausible	³⁰
Multi-methylated fatty acids, i.e., mycocerosates	Methyl malonyl-CoA: folate independent	Must be	Not plausible	^{30,31}

studied. This relative activity is quite high considering the slow growth rate of *M. leprae*, the high proportion of dead and moribund organisms, and in light of the experience with other enzyme assays.¹⁰ Generally, biosynthetic activities that are not used by parasites are selected against, yet *M. leprae* has the capability not only of synthesizing FH₄ but also is known to synthesize methionine¹¹ and the cytosine and thymine bases¹² which depend on FH₄ (Table 2).

Could *M. leprae* manage without folate nevertheless? It takes up serine¹³ and would be expected to take up methionine since this latter activity is enhanced fourfold in *M. avium* when it is grown *in vivo* compared with when it is grown in Sauton's medium.¹⁰ As well as apparently depending upon its host for a supply of purines,¹³ *M. leprae* can

scavenge pyrimidines.¹² However, thymine and thymidine are taken up only very slowly compared with other pyrimidines, uracil and uridine, and thus C-1 units are needed for the conversion of the uracil base to the thymine base, a methylation reaction catalyzed by thymidilate synthase. This enzyme has been shown indirectly.¹² Intriguingly, all of the enzymes for pyrimidine biosynthesis *de novo* can be detected in *M. leprae* even though intact *M. leprae* organisms do not synthesize pyrimidines.¹⁴ Thus, the pathway must be subject to feedback inhibition. Then it is ready to synthesize pyrimidines when the concentration of nucleotides inside the *M. leprae* falls, which could occur when pyrimidines are not available in the host cell for *M. leprae* to scavenge.¹⁴ Perhaps by having not all but the vital biosynthetic capabilities, *M. leprae* is able to withstand attempts by the host to prevent its growth which arise from nutritional immunity—and the folate pathway is one of the vital biosynthetic capabilities.

Even when *M. leprae* is scavenging all of the products that are possible to scavenge (Table 2), using methionine from the host to carry out the methylations to make products which themselves are not available di-

¹⁰ Wheeler, P. R. Enzymes and other metabolically active components of mycobacteria. *Lepr. Rev.* **57** Suppl. 2 (1986) 21–32.

¹¹ Sriharan, V., Ratledge, C. and Wheeler, P. R. Aspartate metabolism in *Mycobacterium avium* grown in host tissue and axenically and in *Mycobacterium leprae*. *J. Gen. Microbiol.* **136** (1990) 203–209.

¹² Wheeler, P. R. Pyrimidine scavenging by *Mycobacterium leprae*. *FEMS Microbiol. Lett.* **57** (1989) 179–184.

¹³ Wheeler, P. R. Biosynthesis and scavenging of purines by pathogenic mycobacteria including *Mycobacterium leprae*. *J. Gen. Microbiol.* **133** (1987) 2999–3011.

¹⁴ Wheeler, P. R. Pyrimidine biosynthesis *de novo* in *Mycobacterium leprae*. *FEMS Microbiol. Lett.* **57** (1989) 185–190.

rectly from the host, there is one product that *M. leprae* must still make itself which requires FH₄. This is formyl-methionyl-t-RNA (f-met-t-RNA). f-Met-t-RNA is the product of a FH₄-dependent transformylase. This t-RNA species is required for the initiation of translation (peptide synthesis), and is universal among bacteria. Both the transformylase and f-met-t-RNA have been confirmed in *M. smegmatis*.^{15, 16}

Rapid effect in DDS in *in vitro* viability assays

In the host, DDS acts slowly. At bactericidal concentrations around 3 μM it takes 4 months to clear 99.9% of the live leprosy bacilli in man (assessed by the kinetic method¹⁷) or it kills 78% of *M. leprae* in mice as judged by the more quantitative proportional bactericidal method.¹⁸ In contrast, in *in vitro* testing systems effects are observed in less than 3 weeks, usually with concentrations which have only a bacteriostatic effect. The most illustrative examples are the inhibition of thymidine incorporation into nucleic acids of *M. leprae* inside macrophages in 2 weeks by 0.14 μM DDS,¹⁹ and the inhibition of hypoxanthine incorporation into nucleic acids of *M. leprae* in just 24 hours by 0.5 μM DDS.²⁰

How can this difference between the speeds of effects of DDS *in vivo* and *in vitro* be explained? Firstly, the measurements are not comparing like with like. The mouse foot-

pad measurements are direct measurements of viability or of infectivity, and require growth of the leprosy bacilli. The *in vitro* measurements are of correlates of viability at best, are observations of metabolic status, and are judged by their ability to show, for instance, drug susceptibility. Usually, in the *in vitro* tests it is the statistically significant inhibition of the activity being measured that is being sought,²¹ and such inhibition may represent an early step in the eventual death or stasis of the microbe that is observed much later, *in vivo*.

Secondly, *M. leprae* organisms may be exquisitely vulnerable in the *in vitro* tests. They are stressed, as evinced by their elaboration of copious heat-shock²² and iron-regulated proteins.²³ Moreover—and this seems to have been overlooked—3',5' nucleotides characteristic of the stringent response are also detected in *M. leprae*.²⁴ All of these separate but related responses are consistent with growth and survival *in vitro*.²⁵ A major consequence of these responses is a metabolism which conserves resources and nutrients—thus RNA and protein biosynthesis are both limited. These stressed *M. leprae* organisms are then further stressed even in the controls in the viability assays by being transferred to an environment in which they cannot grow and—at least when the assays are done with *M. leprae* in macrophages—by being exposed to oxygen radicals. With no prospect of recovery, exposure of the leprosy bacilli to antileprosy agents may show rapid effects. In the case of DDS, starvation of *M. leprae* organisms *in vitro* may result in a decreased

¹⁵ Deobagkar, D. N. and Gopinathan, K. P. Two forms of methionyl-transfer RNA synthetase from *Mycobacterium smegmatis*. *Biochem. Biophys. Res. Commun.* **71** (1976) 939–951.

¹⁶ Deobagkar, D. N. and Gopinathan, K. P. Studies on transfer RNA from mycobacteria. *Can. J. Microbiol.* **24** (1978) 693–702.

¹⁷ Shepard, C. C. A brief review of experiences with short-term clinical trials monitored by mouse foot-pad inoculation. *Lepr. Rev.* **52** (1981) 299–308.

¹⁸ Colston, M. J., Hilson, G. R. F. and Banerjee, D. K. The “proportional bactericidal test”: a method for assessing bactericidal activity of drugs against *Mycobacterium leprae*. *Lepr. Rev.* **49** (1978) 7–15.

¹⁹ Mittal, A., Sathish, M., Seshadri, P. S. and Nath, I. Rapid, radiolabelled microculture method that uses macrophages for *in vitro* evaluation of *Mycobacterium leprae* viability and drug susceptibility. *J. Clin. Microbiol.* **17** (1983) 704–707.

²⁰ Wheeler, P. R. Measurement of hypoxanthine incorporation in purified suspensions of *Mycobacterium leprae*: a suitable method to screen for anti-leprosy agents *in vitro*. *J. Med. Microbiol.* **25** (1988) 167–174.

²¹ Barclay, R. and Wheeler, P. R. Metabolism of mycobacteria in tissues. In: *The Biology of the Mycobacteria*. Vol. 3. Ratledge, C., Stanford, J. and Grange, J. M., eds. London: Academic Press, 1989, pp. 37–106.

²² Young, D. B., Mehlert, A., Bal, V., Samperio, P. M., Ivanyi, J. and Lamb, J. R. Stress proteins and the immune response to mycobacteria—antigens as virulence factors? *Antonie van Leeuwenhoek* **54** (1988) 431–439.

²³ Sritharan, M. and Ratledge, C. Iron-regulated proteins of mycobacteria grown *in vitro* and their occurrence in *Mycobacterium avium* and *Mycobacterium leprae* grown *in vivo*. *Biol. Metals* **2** (1990) 203–208.

²⁴ Lee, Y. N. and Colston, M. J. Measurement of ATP generation and decay in *Mycobacterium leprae* *in vitro*. *J. Gen. Microbiol.* **131** (1985) 3331–3337.

²⁵ Lindquist, S. The heat shock response. *Ann. Rev. Biochem.* **55** (1986) 1151–1192.

level of PABA inside the bacteria and, consequently, increased susceptibility to DDS.

Conclusions and future directions

There is no doubt that DDS is a powerful inhibitor of folate biosynthesis, and that *M. leprae* possess biosynthetic pathways that require folate (in its final, reduced form, FH₄). One product of folate-based (C-1) metabolism that *M. leprae* cannot scavenge from its environment is formyl-methionyl-t-RNA, the universal t-RNA for initiation of translation in bacteria. No doubt because of its universality f-met-t-RNA has never been sought in *M. leprae*: perhaps this editorial will stimulate an examination. My idea that *M. leprae in vitro* is particularly vulnerable to DDS and other antileprosy agents is based on much research. But it is an idea which is, to some extent, an hypothesis and thus makes predictions which are testable. The rates of macromolecular biosynthesis should fall after isolation of *M. leprae*—they must be measured in systems from disrupted *M. leprae* since levels of intracellular pools of intermediates are likely to fall. Intracellular PABA should fall. It is possible that molecules related to stress, such as 3',5' nucleotides and heat-shock proteins, may be synthesized and the latter should soon be known since it is possible to follow synthesis of mRNA for heat-shock proteins

in mycobacteria.²⁶ Intriguingly, by following some of these parameters it may eventually be possible to assess one of the oldest of all problems in leprosy bacteriology: when, if, or how the bacteria are in an environment in which they are close to axenic growth.

—Paul R. Wheeler, Ph.D.

*London School of Hygiene and
Tropical Medicine
Keppel Street
London WC1E 7HT, U.K.*

²⁶ Patel, B. K. R., Banerjee, D. K. and Butcher, P. D. Characterization of the heat shock response in *Mycobacterium bovis* BCG. *J. Bacteriol.* **173** (1991) 7982–7987.

²⁷ Ellard, G. A. The chemotherapy of leprosy. Part 1. *Int. J. Lepr.* **58** (1990) 704–716.

²⁸ Waters, M. F. R. The chemotherapy of leprosy. In: *The Biology of the Mycobacteria. Vol. 3.* Ratledge, C., Stanford, J. and Grange, J. M., eds. London: Academic Press, 1989, pp. 405–476.

²⁹ Zuidema, J., Hilbers-Modderman, E. S. M. and Merkus, F. W. H. M. Clinical pharmacokinetics of dapsone. *Clin. Pharmacokin.* **11** (1986) 299–315.

³⁰ Minnikin, D. E. Lipids: complex lipids, their chemistry, biosynthesis and roles. In: *The Biology of the Mycobacteria. Vol. 1.* Ratledge, C. and Stanford, J., eds. London: Academic Press, 1982, pp. 37–106.

³¹ Rainwater, D. L. and Kolattukudy, P. E. Fatty acid biosynthesis in *Mycobacterium tuberculosis var bovis* BCG; purification and characterization of a novel fatty acid synthase, mycocerosate synthase, which elongates n-fatty acyl CoA with methylmalonyl CoA. *J. Biol. Chem.* **260** (1985) 616–623.